[go: up one dir, main page]

BR9911871A - Derivados de ácido fenoxiacético e composições medicinais contendo os mesmos - Google Patents

Derivados de ácido fenoxiacético e composições medicinais contendo os mesmos

Info

Publication number
BR9911871A
BR9911871A BR9911871-8A BR9911871A BR9911871A BR 9911871 A BR9911871 A BR 9911871A BR 9911871 A BR9911871 A BR 9911871A BR 9911871 A BR9911871 A BR 9911871A
Authority
BR
Brazil
Prior art keywords
phenoxyacetic acid
compositions containing
same
medicinal compositions
derivatives
Prior art date
Application number
BR9911871-8A
Other languages
English (en)
Other versions
BR9911871B1 (pt
Inventor
Nobuyuki Tanaka
Tetsuro Tamai
Harunobu Mukaiyama
Akihito Hirabayashi
Hideyuki Muranaka
Masaakisato
Masuo Akahane
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of BR9911871A publication Critical patent/BR9911871A/pt
Publication of BR9911871B1 publication Critical patent/BR9911871B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Maintenance And Inspection Apparatuses For Elevators (AREA)

Abstract

"DERIVADOS DE áCIDO FENOXIACéTICO E COMPOSIçõES MEDICINAIS CONTENDO OS MESMOS" A presente invenção proporciona novos derivados de ácido fenoxiacético, representados pela fórmula geral acima descrita, e os sais farmaceuticamente aceitáveis dos mesmos, os quais têm excelentes efeitos estimulantes do adrenoceptor <225>~ 3~ e são úteis como agentes para a prevenção ou o tratamento de obesidade, hiperglicemia, das doenças causadas por hipermotilidade intestinal, polaciúria, incontinência urinária, depressão, ou das doenças causadas por cálculos biliares ou hipermotilidade do trato biliar. (Na fórmula geral, R¹ representa um grupo hidróxi etc.; um de R² e R³ é um átomo de hidrogênio, um átomo de halogênio etc., enquanto que o outro é um átomo de hidrogênio; R^ 4^ representa um átomo de halogênio etc.)
BRPI9911871-8A 1998-07-08 1999-07-05 derivados de ácido fenoxiacético e composições farmacêuticas contendo os mesmos. BR9911871B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22850198 1998-07-08
PCT/JP1999/003611 WO2000002846A1 (fr) 1998-07-08 1999-07-05 Derives d'acide phenoxyacetique et compositions medicinales contenant lesdits derives

Publications (2)

Publication Number Publication Date
BR9911871A true BR9911871A (pt) 2001-03-27
BR9911871B1 BR9911871B1 (pt) 2010-10-19

Family

ID=16877446

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9911871-8A BR9911871B1 (pt) 1998-07-08 1999-07-05 derivados de ácido fenoxiacético e composições farmacêuticas contendo os mesmos.

Country Status (27)

Country Link
US (1) US6538152B1 (pt)
EP (1) EP1095932B1 (pt)
JP (2) JP4132010B2 (pt)
KR (1) KR100516277B1 (pt)
CN (1) CN1242983C (pt)
AR (1) AR029600A1 (pt)
AT (1) ATE267161T1 (pt)
AU (1) AU771200B2 (pt)
BR (1) BR9911871B1 (pt)
CA (1) CA2336853C (pt)
CO (1) CO5070574A1 (pt)
CZ (1) CZ302727B6 (pt)
DE (1) DE69917459T2 (pt)
DK (1) DK1095932T3 (pt)
ES (1) ES2221390T3 (pt)
HU (1) HUP0103008A3 (pt)
IL (1) IL140498A (pt)
MY (1) MY126489A (pt)
NO (1) NO327770B1 (pt)
NZ (1) NZ509203A (pt)
PE (1) PE20000758A1 (pt)
PL (1) PL197453B1 (pt)
PT (1) PT1095932E (pt)
SA (1) SA99200411B1 (pt)
TW (1) TW432040B (pt)
WO (1) WO2000002846A1 (pt)
ZA (1) ZA200100135B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ585000A0 (en) * 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
ES2314092T3 (es) * 2001-09-13 2009-03-16 Kissei Pharmaceutical Co., Ltd. Cristales de un derivado de hidroxinorefredina.
UA79498C2 (en) 2002-09-05 2007-06-25 Kissei Pharmaceutical Intermediates for preparation of phenoxy-acetic derivates and processes of their preparation
USRE44872E1 (en) * 2002-11-07 2014-04-29 Astellas Pharma Inc. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
AU2004236596B2 (en) * 2003-05-05 2010-03-11 Kissei Pharmaceutical Co., Ltd. Use of phenoxyacetic acid derivatives for treating hyperactive bladder
DE10320084A1 (de) * 2003-05-05 2004-11-25 Kissei Pharmaceutical Co., Ltd., Matsumoto Verwendung von Phenoxyessigsäurederivaten zur Behandlung der hyperaktiven Blase
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
EP1682183A2 (de) * 2003-11-03 2006-07-26 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einem alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
DE10352132A1 (de) * 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
DE10356112A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
WO2005092321A1 (ja) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. 頻尿または尿失禁の予防または治療用医薬組成物
JP4808613B2 (ja) * 2004-03-24 2011-11-02 キッセイ薬品工業株式会社 頻尿または尿失禁の予防または治療用医薬
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
WO2006042679A1 (de) * 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
CA2585037A1 (en) 2004-10-26 2006-05-04 Kissei Pharmaceutical Co., Ltd. Synthesis of phenoxyacetic acid derivatives
TWI356699B (en) * 2004-11-10 2012-01-21 Kissei Pharmaceutical Agent for treating interstitial cystitis and agent
LT5282B (lt) 2005-02-28 2005-10-25 Kissei Pharmaceutical Co., Ltd. Tarpiniai junginiai fenoksiacto rūgšties darinių gamyboje ir jų panaudojimo būdas
US7763654B2 (en) * 2005-04-26 2010-07-27 Kissei Pharmaceutical Co., Ltd. Crystal polymorph of hydroxynorephedrin derivative hydrochloride
WO2006118087A1 (ja) 2005-04-26 2006-11-09 Kissei Pharmaceutical Co., Ltd. ヒドロキシノルエフェドリン誘導体塩酸塩・１／４水和物の結晶
ZA200801858B (en) * 2005-08-29 2009-07-29 Kissei Pharmaceutical Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid
EP1769792A1 (de) * 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
JPWO2007083640A1 (ja) * 2006-01-18 2009-06-11 杏林製薬株式会社 頻尿及び尿失禁の予防又は治療剤
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
JP5849947B2 (ja) 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
WO2014108449A1 (en) 2013-01-08 2014-07-17 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6401871A (pt) * 1964-02-27 1965-08-30
EP0023385B1 (en) * 1979-06-16 1982-12-15 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
GB8418472D0 (en) * 1984-07-19 1984-08-22 Beecham Group Plc Compounds
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
AU4320297A (en) 1996-09-26 1998-04-17 Kissei Pharmaceutical Co. Ltd. 2-amino-1-(4-hydroxy-2-methylphenyl)propanol derivatives
ID24062A (id) * 1997-07-25 2000-07-06 Kissei Pharmaceutical Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing

Also Published As

Publication number Publication date
MY126489A (en) 2006-10-31
JP4871321B2 (ja) 2012-02-08
AU771200B2 (en) 2004-03-18
PT1095932E (pt) 2004-09-30
SA99200411B1 (ar) 2006-09-09
KR100516277B1 (ko) 2005-09-21
AR029600A1 (es) 2003-07-10
NZ509203A (en) 2003-03-28
TW432040B (en) 2001-05-01
CN1308603A (zh) 2001-08-15
WO2000002846A1 (fr) 2000-01-20
ZA200100135B (en) 2001-12-10
NO327770B1 (no) 2009-09-21
IL140498A0 (en) 2002-02-10
NO20010078D0 (no) 2001-01-05
AU4397399A (en) 2000-02-01
NO20010078L (no) 2001-03-08
HUP0103008A2 (hu) 2001-12-28
EP1095932B1 (en) 2004-05-19
HUP0103008A3 (en) 2002-12-28
DE69917459D1 (de) 2004-06-24
IL140498A (en) 2004-06-20
PE20000758A1 (es) 2000-09-04
CO5070574A1 (es) 2001-08-28
BR9911871B1 (pt) 2010-10-19
JP2008273965A (ja) 2008-11-13
CZ200173A3 (cs) 2002-01-16
DE69917459T2 (de) 2005-05-12
KR20010071772A (ko) 2001-07-31
CA2336853C (en) 2009-03-10
EP1095932A4 (en) 2002-10-16
DK1095932T3 (da) 2004-09-20
ATE267161T1 (de) 2004-06-15
JP4132010B2 (ja) 2008-08-13
CN1242983C (zh) 2006-02-22
PL197453B1 (pl) 2008-04-30
US6538152B1 (en) 2003-03-25
CA2336853A1 (en) 2000-01-20
EP1095932A1 (en) 2001-05-02
PL345730A1 (en) 2002-01-02
CZ302727B6 (cs) 2011-09-29
HK1039480A1 (en) 2002-04-26
ES2221390T3 (es) 2004-12-16

Similar Documents

Publication Publication Date Title
BR9911871A (pt) Derivados de ácido fenoxiacético e composições medicinais contendo os mesmos
BR0212378A (pt) Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio
BR0013667A (pt) Derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos derivados e seus intermediários na produção dos mesmos
BRPI0415746A (pt) derivados de amida
BR9804500A (pt) Derivados de amida ou sais dos mesmos.
BR0312095A (pt) Composto, composição farmacêutica, e, uso de um composto
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
BRPI0417687A (pt) derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
BR0014179A (pt) Modernos derivados de ácido aminodicarboxìlico com propriedades farmacêuticas
BR0015624A (pt) Uso de um composto, composto, composição farmacêutica, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR9813360A (pt) Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz (mmp)
BR0014060A (pt) Derivado de quinolil propil piperidina, processo para preparação do mesmo, e, composição farmacêutica
BR9807339A (pt) Derivados 3-piperidil-4-oxoquinazolina e composições farmacêuticas compreendendo os mesmos.
BR9813973A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição.
BR9909908A (pt) Derivados de ácidos graxos de ácidos biliares e derivados de ácidos biliares
BRPI0508243A (pt) derivados de anéis fundidos nitrogenados, composições medicinais contendo os derivados e uso destas como drogas
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
BR0313846A (pt) Derivados de dioxano-2-alquilcarbamatos, sua preparação e sua aplicação em terapêutica
BR0014895A (pt) Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais
ATE411276T1 (de) Kristalle eines hydroxynorephedrinderivats
MY120466A (en) Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same.
BR0107912A (pt) Composto, composições, e, métodos para tratar ou prevenir o c ncer ou doença neoplástica, método para inibir o desenvolvimento de uma célula cancerìgena ou célula neoplástica, método para tratar ou prevenir uma infecção viral em um paciente, e para inibir a replicação ou a infectividade de um vìrus
BR9911611A (pt) Fenóis rádio-iodados para braquiterapia
BR0008437A (pt) Inibidores esteróides de sulfatase e métodos parafabricação e uso dos mesmos
CA2417492A1 (en) Preventives or remedies for obesity or fatty liver

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/10/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2261 DE 06-05-2014 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.